Data Indicate That SuperGen’s Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation In Non Clinical Models

SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, announced the presentation of data that describe how its lead JAK2 kinase inhibitors prevent cancer cell proliferation in non-clinical models (Poster 779, Abstract 3560). [click link for full article]

More: continued here

Filed under: Cancer on December 11th, 2007